34 related articles for article (PubMed ID: 27256047)
1. Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis.
Ding M; Li M; Liu Q; Xu L
J Cancer Res Clin Oncol; 2024 Jun; 150(6):297. PubMed ID: 38850362
[TBL] [Abstract][Full Text] [Related]
2. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
Kochi M; Fujii M; Masuda S; Kanamori N; Mihara Y; Funada T; Tamegai H; Watanabe M; Suda H; Takayama T
Diagn Pathol; 2013 Nov; 8():191. PubMed ID: 24261710
[TBL] [Abstract][Full Text] [Related]
3. HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.
Ataseven B; Gologan D; Gunesch A; Kehl V; Hoegel B; Beer M; Eiermann W
Breast Care (Basel); 2012 Dec; 7(6):465-70. PubMed ID: 24715828
[TBL] [Abstract][Full Text] [Related]
4. Alteration of HER2 status during breast cancer progression: a clinicopathological analysis focusing on HER2-low status.
Bai K; Woo JW; Kwon HJ; Chung YR; Suh KJ; Kim SH; Kim JH; Park SY
Lab Invest; 2024 Jun; ():102092. PubMed ID: 38857783
[TBL] [Abstract][Full Text] [Related]
5. The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy.
Kumthekar PU; Blouw B; Corkos P; Nagpal S; Tripathy A; Piccioni D; Youssef M
Front Oncol; 2024; 14():1402651. PubMed ID: 38826788
[TBL] [Abstract][Full Text] [Related]
6. Is Metastatic Staging Needed for All Patients with Synchronous Bilateral Breast Cancers?
Lim GH; Hoo JX; Shin YC; Choo RZT; Wong FY; Allen JC
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201445
[TBL] [Abstract][Full Text] [Related]
7. Primary breast cancer with synchronous contralateral axillary lymph node metastasis: A case report.
Xiao J; Luo J
Asian J Surg; 2024 Apr; ():. PubMed ID: 38641530
[No Abstract] [Full Text] [Related]
8. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].
Liu YY; Wu SF; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):393-6. PubMed ID: 27256047
[TBL] [Abstract][Full Text] [Related]
10. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
11. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
12. [HER2 gene status and mRNA expression in immunohistochemistry 1+ breast cancer].
Wu SF; Liu YY; Liu XD; Jiang Y; Luo YF; Cui QC; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):522-526. PubMed ID: 29996317
[No Abstract] [Full Text] [Related]
13. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
14. Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients.
Baroš IV; Tanasković N; Pellas U; Eri Ž; Tadić Latinović L; Tot T
Bosn J Basic Med Sci; 2019 Aug; 19(3):242-248. PubMed ID: 30957723
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
